Company intelligence / Profile preview

Rhythmia Medical

Burlington, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Rhythmia Medical developed an advanced cardiac mapping system intended to improve electrophysiology ablation procedures for arrhythmia, acquired by Boston Scientific in 2012 for up to $265 million. Market launch was expected in 2014 after FDA clearance and CE mark approval; no independent clinical results published yet as Rhythmia products are now under Boston Scientific umbrella

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Boston Scientific

Beyond the preview

Go deeper on Rhythmia Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhythmia Medical.

Explore the full profile